DOES MODERATE CYP3A4 INHIBITION REQUIRE VENETOCLAX DOSE REDUCTION IN ACUTE MYELOID LEUKEMIA? REAL-WORLD EVIDENCE WITH ISAVUCONAZOLE. (EHA 2026) - May 12, 2026 - Abstract #EHA-6867; PB2778; "Survival curves estimated by the Kaplan–Meier method and compared using the log-rank test. Tick marks represent censored patients."
Clinical • HEOR • Real-world • Real-world evidence • Acute Myelogenous Leukemia • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Neutropenia • Sarcoma • Solid Tumor • Thrombocytopenia
|
|
María Ibáñez Lacalle 1; Rodrigo Cantera Estefanía 1; Nerea Elorza Odriozola 1; Amaia Aldea García de Vicuña 1; María Elena Sola Aparicio 1; Beatriz Larrayoz Sola 1; Maria Piva Sanchez Anton 1; Mª Ángeles Goñi Hernández 1; Blai Signes Fort 1; Ernesto Pérez Persona 1; José María Arguiñano 1; Ana Gorena Nicuesa 1; Amaya Zabalza San Martín 1; Maite Zudaire Ripa 1; Maria Carmen Mateos Rodriguez 1; Ana Margarita Redondo Izal1
|